Rare Daily Staff
China-based CureGenetics said it closed a $17 million series A financing, which will be used to optimize its gene editing and delivery platform, advance to human clinical trials, and develop its pipeline.
Qiming Venture Partners led the financing with CTS Capital and Ascendin Investment also participating in the round.
“Being a unique player of this field, we have recruited top-tier scientists and business partners to develop and promote our proprietary technology platform,” said Yuanyuan Xu, co-founder and CEO of CureGenetics. “We are delighted by the votes of confidence from all the investors, and this financing puts us in strong position to accelerate the development of multiple pipelines, and to keep investing in these game-changing technologies.”
Established in 2016, CureGenetics is a biotechnology company co-founded by pioneers in CRISPR enabled applications. With its gene editing and delivery platforms, the company is committed to developing applications of gene-editing technology in medicines and molecular diagnostics that will contribute to treating easy-to-relapse or hard-to-treat cancers and genetic diseases.
August 6, 2018